Trial Profile
An observational study to evaluate the incidence of anti-drug antibodies in patients with rheumatoid arthritis treated with adalimumab, etanercept or infliximab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Therapeutic Use
- 09 Feb 2016 New trial record